| Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients (NCT02246686) | Bayer | 2014-11-01 |
| The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis (NCT02469103) | Chinese University of Hong Kong | 2014-10-01 |
| Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics (NCT02316678) | University of Pennsylvania | 2014-09-01 |
| A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors (NCT02165215) | Hoffmann-La Roche | 2014-08-12 |
| Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea (NCT02229344) | Janssen Korea, Ltd., Korea | 2014-07-01 |
| Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease (NCT02085083) | Mount Sinai Hospital, Canada | 2014-07-01 |
| Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU) (NCT02943538) | Instituto de Investigacion Sanitaria La Fe | 2014-05-01 |
| Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients (NCT02129439) | Sterna Biologicals GmbH & Co. KG | 2014-04-01 |
| Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease (NCT01908283) | Klara M. Pósfay Barbe | 2014-03-01 |
| Randomized-controlled Trial of Yoga for Ulcerative Colitis (NCT02043600) | Universität Duisburg-Essen | 2014-02-01 |
| Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (NCT01984047) | GlaxoSmithKline | 2014-01-10 |
| Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. (NCT02000453) | GlaxoSmithKline | 2013-12-20 |
| A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT01988961) | Janssen Research & Development, LLC | 2013-12-01 |
| A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis (NCT01959282) | Janssen Research & Development, LLC | 2013-11-15 |
| Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis (NCT01953354) | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-11-01 |
| A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis (NCT01900574) | Janssen Research & Development, LLC | 2013-08-09 |
| A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. (NCT01863771) | Janssen Pharmaceutical K.K. | 2013-03-15 |
| Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases (NCT01990716) | University Hospital, Toulouse | 2013-02-01 |
| Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment (NCT01684514) | Herlev Hospital | 2012-10-01 |
| A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing (NCT01880918) | novoGI | 2012-10-01 |
| Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients (NCT01604564) | Universitaire Ziekenhuizen KU Leuven | 2012-05-01 |
| A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis (NCT01453491) | Sirtris, a GSK Company | 2012-02-13 |
| Immune Modulation From Trichuris Trichiura (NCT02399683) | University of Aarhus | 2012-02-01 |
| Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) (NCT01534312) | University of Aarhus | 2012-01-01 |
| The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients (NCT01493960) | InDex Pharmaceuticals | 2011-12-01 |
| Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients (NCT01284062) | Pfizer | 2011-03-01 |
| Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis (NCT01294410) | Bristol-Myers Squibb | 2011-03-01 |
| Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis (NCT01301417) | novoGI | 2011-02-01 |
| A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis (NCT01240915) | Pfizer | 2011-02-01 |
| Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders (NCT01099111) | King Fahad Medical City | 2010-07-01 |
| Mesalamine and Reproductive Health Study (NCT01331551) | Harvard School of Public Health (HSPH) | 2010-05-01 |
| (CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets (NCT01100112) | Bausch Health Americas, Inc. | 2010-02-01 |
| Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553) (NCT00984568) | Merck Sharp & Dohme LLC | 2009-11-01 |
| Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis (NCT01036022) | GlaxoSmithKline | 2009-09-15 |
| Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis (NCT00748410) | GlaxoSmithKline | 2009-01-22 |
| Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis (NCT00676832) | Prometheus Laboratories | 2008-05-01 |
| Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) (NCT00747110) | Dr. Falk Pharma GmbH | 2007-10-01 |
| An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT00488631) | Janssen Research & Development, LLC | 2007-09-01 |
| An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT00487539) | Janssen Research & Development, LLC | 2007-08-01 |
| An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis (NCT00488774) | Janssen Research & Development, LLC | 2007-08-01 |
| Antibiotics for the Treatment of Ulcerative Colitis (NCT00355602) | University of Dundee | 2006-07-01 |
| A Dose-finding Study of OPC-6535 in Patients With Active Ulcerative Colitis (NCT00317356) | Otsuka Pharmaceutical Co., Ltd. | 2006-05-01 |
| Compare Conventional Colonosocpy to Endoscopic AFI, NBI for Dysplasia Detection for Ulcerative Colitis & Cholangitis (NCT00587236) | Mayo Clinic | 2006-03-01 |
| Follow-Up Phone Calls After Colorectal Surgery (NCT00474097) | University Hospitals Cleveland Medical Center | 2006-02-01 |
| Post-Op Quality of Life After Colorectal Surgery (NCT00468455) | University Hospitals Cleveland Medical Center | 2005-10-01 |
| A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis (NCT00928681) | Pfizer | 2005-09-01 |
| A Study to Investigate the Ileo Neo Rectal Anastomosis Compared to the Ileo Pouch Anal Anastomosis for Patients With Ulcerative Colitis (NCT00922103) | Elisabeth-TweeSteden Ziekenhuis | 2005-06-01 |
| Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC) (NCT00746447) | Dr. Falk Pharma GmbH | 2005-05-01 |
| Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis. (NCT00151944) | Shire | 2003-11-26 |
| Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis (NCT00503243) | Shire | 2003-09-30 |
| Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (NCT00545389) | Shire | 2003-02-10 |
| Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients. (NCT06025227) | Pfizer | |